Details of Disease

General Information of Disease (ID: DIS1A2OI)

Disease Name	Clostridioides difficile infection
Synonyms	pseudomembranous colitis; Clostridium difficile infection; Clostridioides difficile colitis (disease); Clostridioides difficile caused colitis (disease); C. diff infection; C. diff colitis
Disease Class	1A04: Clostridium difficile enterocolitis
Definition	A bacterial infection of the colon secondary to infection with Clostridium difficile bacteria. This infection generally results from the loss of normal gut flora secondary to recent antibiotic use, and manifests as copious watery stools, with associated abdominal pain and myalgia. C. difficile is the most common cause of pseudomembranous colitis, and can progress to toxic megacolon if left untreated.
Disease Hierarchy	DIS5QJ9S: Bacterial infection DISAF7DD: Colitis DISEM33Q: Infectious disease DISKN090: Infectious colitis DIS1A2OI: Clostridioides difficile infection
ICD Code	ICD-11 ICD-11: 1A04
Disease Identifiers	MONDO ID MONDO_0000705 MESH ID D003015 UMLS CUI C0238106 MedGen ID 65946 HPO ID HP:0032168 SNOMED CT ID 423590009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Fidaxomicin	DMFP6MV	Approved	Small molecular drug	[1]
Nitazoxanide	DMOWLVG	Approved	Small molecular drug	[2]
Vancomycin	DM3JFIH	Approved	NA	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NTCD-M3	DMPMTW9	Phase 2	Live biotherapeutic	[4]
ART24	DMO93S0	Phase 1	Live biotherapeutic	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DEFA6	OTDJADMQ	Limited	Biomarker	[6]
------------------------------------------------------------------------------------

References

1	Fidaxomicin FDA Label
2	Nitazoxanide FDA Label
3	Vancomycin FDA Label
4	Clinical pipeline report, company report or official report of Destiny Pharma
5	ClinicalTrials.gov (NCT04891965) A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI). U.S.National Institutes of Health.
6	Activation of REG family proteins in colitis.Scand J Gastroenterol. 2011 Nov;46(11):1316-23. doi: 10.3109/00365521.2011.605463.